ClinicalTrials.gg
CompletedNCT03393494Updated Nov 8, 2021Results posted

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

A Phase 3 interventional study of Adapalene and Benzoyl Peroxide Topical Gel and Epiduo Topical Product in Acne Vulgaris, sponsored by Padagis LLC. Completed at 1 site in United States. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-11-08.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
825
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies in Acne Vulgaris with a site in United States — 19 open to participants now, 28 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
39th of 353
825 · median 78
Started
2017
with 22 others
Phase 3
76 of 373
1 open now
Registered
241st of 373
by date

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 39th largest by enrollment of the 353 interventional ones that give a count, is one of 23 that started in 2017, is one of 76 in phase 3, and was the 241st registered.

Acne Vulgaris

792 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

19 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Acne Vulgaris studies recruiting now, 15 (33%) set no upper age limit and 29 (64%) stop at 75 or younger; 20 take children under 18; 16 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

To compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of Acne Vulgaris

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed IRB approved written /assent
  2. 12 to 40 years of age, inclusive.
  3. Clinical diagnosis of facial acne vulgaris with an inflammatory lesion (papules and pustules) count of 20-50, inclusive and a non-inflammatory (open and closed comedones) lesion count of 25-100 inclusive and no more than 2 nodulocystic lesions (e.g., nodules and cysts) including those present on the nose.
  4. Baseline Investigator's Global Assessment Score of 3 (moderate) or 4 (severe) on a severity scale of 0 to 4.
  5. Females of child bearing potential (excluding women who are surgically sterilized (tubal ligation or bilateral oophorectomy or hysterectomy) or for at least 2 years), in addition to having a negative urine pregnancy test at Visit 1/Day1(Baseline), must be willing to use an acceptable form of during the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, breastfeeding or planning a pregnancy within the period of their study participation period.
  2. Presence of more than 2 facial Nodulocystic lesions.
  3. Presence of any other facial skin condition that, in the Investigator's opinion, might interfere with acne vulgaris diagnosis and/or evaluations
  4. Any uncontrolled, chronic or serious disease or medical condition that would prevent participation in a clinical trial, or, in judgment of the investigator, would put the subject at undue risk or might confound the study assessments
  5. Excessive facial hair that would interfere with the diagnosis or assessment of acne vulgaris.
  6. History of unresponsiveness to topical adapalene and/or benzoyl peroxide therapy.
  7. Currently using any product containing adapalene and/or benzoyl peroxide and/or belonging to the same family.
  8. History of or allergy to adapalene, benzoyl peroxide, retinoids and/or any ingredient in the study medication.
  9. Use of medications known to exacerbate acne
  10. Start or change within 3 months (90 days) of Visit 1 and throughout the study
  11. Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days (1 month) of study entry and throughout the study
  12. Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
  13. Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
825 participants (actual)

Study arms

  • Experimental
    Perrigo active

    Test product

    Drug: Adapalene and Benzoyl Peroxide Topical Gel

  • Active comparator
    Reference active

    RLD product

    Drug: Epiduo Topical Product

  • Placebo comparator
    Perrigo placebo

    placebo product

    Drug: Placebo

Interventions

  • DrugAdapalene and Benzoyl Peroxide Topical Gel

    Test product

  • DrugEpiduo Topical Product

    RLD product

  • DrugPlacebo

    Placebo gel

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in the Papules and Pustules Lesion Count

    Time frame: Day 1 to week 12

  2. Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count

    Per protocol population

    Time frame: Day 1 to week 12

07

Results

Posted Jan 5, 2021

Participant flow

Participant flow — Overall Study
MilestoneTest ProductReference ProductPlacebo Product
Started329331165
Completed261256140
Not completed687525

Outcome measures

PrimaryMean Percent Change From Baseline in the Papules and Pustules Lesion Count
Time frame:
Day 1 to week 12
Reported as:
Mean · percentage of lesion change
Mean Percent Change From Baseline in the Papules and Pustules Lesion Count
percentage of lesion changePerrigo ActiveReference ActivePerrigo Placebo
Mean Percent Change From Baseline in the Papules and Pustules Lesion Count68.18 ± 28.9663.56 ± 31.5750.72 ± 35.12
Statistical analysis
  • Perrigo Active vs Reference Active · Fieller's method · Equivalence ratio: 107 · 90% CI 97.8 to 112.2
PrimaryMean Percent Change From Baseline in the Open and Closed Comedones Lesion Count

Per protocol population

Time frame:
Day 1 to week 12
Reported as:
Mean · percentage of lesion change
Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count
percentage of lesion changePerrigo ActiveReference ActivePerrigo Placebo
Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count62.75 ± 28.0960.78 ± 33.7343.45 ± 36.30
Statistical analysis
  • Perrigo Active vs Reference Active · Fieller's method · p = 0.05 · Equivalence ratio: 104 · 90% CI 94.1 to 108.5

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Perrigo Active0/329 (0%)0/329 (0%)0/329 (0%)
Reference Active0/331 (0%)0/331 (0%)0/331 (0%)
Perrigo Placebo0/165 (0%)2/165 (1.2%)0/165 (0%)
Most frequent serious events
Most frequent serious events
EventPerrigo ActiveReference ActivePerrigo Placebo
Cervical RadiculopathyNervous system disorders0/3290/3311/165
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/3290/3311/165

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Perrigo ActiveReference ActivePerrigo PlaceboTotal
<=18 years16016176397
Between 18 and 65 years16917089428
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Perrigo ActiveReference ActivePerrigo PlaceboTotal
Female11712969315
Male21220296510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Perrigo ActiveReference ActivePerrigo PlaceboTotal
Hispanic or Latino12612053299
Not Hispanic or Latino203211112526
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Perrigo ActiveReference ActivePerrigo PlaceboTotal
American Indian or Alaska Native2204
Asian136423
Native Hawaiian or Other Pacific Islander1001
Black or African American514830129
White241256122619
More than one race0000
Unknown or Not Reported2119949
08

Study locations

1 site
  • Dermatology Consultants
    High Point, North Carolina 27262, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Sep 2018, 9 months.

Results were first posted in Jan 2021, 2 years 3 months after primary completion. A results delay was requested in Oct 2019.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 9 months is below that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2018
First posted
Jan 8, 2018
StartActual
Dec 13, 2017
Primary completionActual
Sep 30, 2018
CompletionActual
Jan 5, 2019
Results delay requested
Oct 8, 2019
Results first posted
Jan 5, 2021
Last update
Nov 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03393494
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Jan 8, 2018
Start date
Dec 13, 2017
Primary completion
Sep 30, 2018
Completion
Jan 5, 2019
Results posted
Jan 5, 2021
Last update
Nov 8, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion